‘Beautiful, powerful moment’ and Twitter buzz after DESTINY-Breast04 data presented
Click Here to Manage Email Alerts
Eleanora Teplinsky, MD (@drteplinsky). June 5, 2022. Standing ovation for results of DESTINY-Breast04. This will change practice for 50% of patients with metastatic breast cancer. This is why we all went into this field. #bcsm #ASCO22. [Video in original post.] Twitter.
Paolo Tarantino (@PTarantinoMD). June 5, 2022. Standing ovation after the #ASCO22 Plenary presentation of DESTINY-Breast04 by Dr. Shanu Modi. A beautiful, powerful moment, that will remain in the history of breast oncology. Twitter.
So far, Tarantino’s tweet has garnered more than 650 likes and 65 retweets, and here is why.
The researchers randomly assigned patients 2:1 to 5.4 mg/kg trastuzumab deruxtecan (n = 373) or physician’s choice of chemotherapy (n = 184), including capecitabine, eribulin, gemcitabine, paclitaxel or nab-paclitaxel, as reported earlier by Healio.
Results showed median progression-free survival of 9.9 months (95% CI, 9-11.3) among patients assigned trastuzumab deruxtecan compared with 5.1 months (95% CI, 4.2-6.8) among those assigned physician’s treatment choice (HR = 0.5; 95% CI, 0.4-0.63).
The researchers also reported longer median overall survival with trastuzumab deruxtecan (23.4 months; 95% CI, 20-24.8) compared with physician’s choice (16.8 months; 95% CI, 14.5-20) for an HR of 0.64 (95% CI, 0.49-0.84).
Physicians reacted to the clinical data that was presented by Shanu Modi, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center.
Margaret Gatti-Mays MD MPH FACP (@DrGattiMays). June 5, 2022. DESTINY-Breast04 results are practice changing with #TDxD showing benefit in low HER2 expressing tumors irrespective of ER status. Potential improvement in PFS and OS for ~50% of pretreated breast patients #bcsm #ASCO22. Twitter.
Dr Billy and bourbon (@drbillyirvin). June 5, 2022. #ASCO22 @OncoAlert destiny Breast04 stunning, practice changing data. Clinically meaningful improvements in PFS and OS in all analyses. OS 23.4 mo vs 17.5 no in all patients. Tears of joy, this will lead to more advances. Lucky to be here in person. Twitter.
To date, tweets since the presentation have been overwhelmingly positive; 27% of all tweets about the trial mentioned the standing ovation. DESTINY-Breast04 was mentioned three times more than TROPiCS-02 during ASCO meeting. DESTINY-Breast04 was mentioned 654 times by health care practitioners, whereas 147 health care practitioners mentioned the TROPiCS-02 trial, also a phase 3 trial in advanced breast cancer.
Dear Dr. Researcher, PhD (@corrie_painter). June 5, 2022. Destiny breast04, great results, practice changing for HER2low and mTNBC. Watching with my MBC friends, all of us with tears in our eyes. Met in the moment by a standing ovation #ASCO22. [Images in original post.] Twitter.
For more information:
Creation Healthcare is a specialist digital insights consultancy providing research and analysis to inform health strategy, communications and policymaking among some of the world’s largest health care companies, government organizations and non-government organizations.
Collapse
Read more about
Click Here to Manage Email Alerts